Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty ImagesSOPA Images/LightRocket via Getty ImagesHere’s why we believe Regeneron Pharmaceuticals (REGN) stock merits attention as a value addition. Currently, it is trading almost 44% lower than its 1-year peak and is also priced at a PS multiple below its average from the last 3 years. Nonetheless, it possesses solid fundamentals relative to its valuation.Sound Revenue Growth: 5.4% LTM and 0.3% average over the last 3 years.Cash Generative: ...